INGN Stock Recent News
INGN LATEST HEADLINES
Teleflex, Integer Holdings and Inogen are defying tariff and supply chain headwinds with genAI-driven momentum within the Medical Instruments industry.
The mean of analysts' price targets for Inogen (INGN) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Inogen, Inc. (NASDAQ:INGN ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Kevin R. M. Smith - President, CEO & Director Lorna Williams - Corporate Participant Michael J.
INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.
Inogen (INGN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.24 per share a year ago.
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025.
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy.
B. Riley initiated coverage of Inogen with a Buy rating and $14 price target.
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.